The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10148 malaria professionals are enjoying the free benefits of MalariaWorld today

Dakar

Relationship between Antibody Levels, IgG Binding to Plasmodium falciparum-Infected Erythrocytes, and Disease Outcome in Hospitalized Urban Malaria Patients from Dakar, Sénégal

August 29, 2016 - 15:18 -- Open Access
Author(s): 
Babacar Mbengue, Mouhamadou Mansour Fall, Ronald Perraut, et al.
Reference: 
BioMed Research International, Volume 2016 (2016)

We found a significant decrease of LIR in adult CM fatal cases compared to surviving patients (). In MM, LIRs were correlated to IgG anti-iRBC and anti-PfEMP3/5 levels. In CM, no correlation was found between LIR, IgG levels, and parasitemia. 

Country: 
City: 

In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na+/H+ exchanger transporter (Pfnhe-1) gene in 393 isolates from Dakar, Senegal

June 14, 2013 - 12:59 -- Open Access
Author(s): 
Pascual A, Fall B, Wurtz N, Fall M, Camara C, Nakoulima A, Baret E, Diatta B, Ba Fall K, Saliou Mbaye P, Diémé Y, Bercion R, Bogreau H, Briolant S, Rogier C, Wade B, Pradines B
Reference: 
Malaria Journal 2013, 12:189 (7 June 2013)
MalariaWorld

Although the World Health Organization recommends replacing quinine (QN) by artesunate due to its increased efficacy and the higher tolerance to the drug in both adults and children, QN remains a first-line treatment for severe malaria, especially in Africa. 

Country: 
City: 

Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal

June 20, 2012 - 08:59 -- Kabogo Ndegwa
Author(s): 
Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Bercion R, Briolant S, Wade B, Pradines B
Reference: 
Malaria Journal 2012, 11:197 (13 June 2012)

MalariaWorldSince 2004, the prevalence of chloroquine resistance had decreased.

Country: 
City: 
Medical Treatment: 

Open Access | Conditions of malaria transmission in Dakar from 2007 to 2010

October 25, 2011 - 08:52 -- Kabogo Ndegwa
Author(s): 
Gadiaga L, Machault V, Pages F, Gaye A, Jarjaval F, Godefroy L, Cisse B, Lacaux J, Sokhna C, Trape J, Rogier C
Reference: 
Malaria Journal 2011, 10:312 (21 October 2011)

MalariaWorldThe spatial and temporal heterogeneity of An. gambiae s.l. larval density, adult human-biting rate (HBR) and malaria transmission in Dakar has been confirmed, and the environmental factors associated with this heterogeneity have been identified.

City: 

Open Access | Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs

October 25, 2011 - 08:43 -- Kabogo Ndegwa
Author(s): 
Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Dieme Y, Rogier C, Wade B, Bercion R, Pradines B
Reference: 
Malaria Journal 2011, 10:310 (20 October 2011)

MalariaWorldThe introduction of ACT in 2002 has not induced a decrease in P. falciparum susceptibility to the drugs DHA, MDAQ and LMF, which are common ACT components. However, the prevalence of P. falciparum isolates with reduced susceptibility has increased for both MQ and DOX.

Country: 
City: 
Medical Condition: 
Medical Treatment: 

Open Access | Spatial heterogeneity and temporal evolution of malaria transmission risk in Dakar, Senegal, according to remotely sensed environmental data

September 7, 2010 - 14:15 -- Kabogo Ndegwa
Author(s): 
Machault V, Vignolles C, Pages F, Gadiaga L, Gaye A, Sokhna C, Trape J, Lacaux J, Rogier C
Reference: 
Malaria Journal 2010, 9:252 (3 September 2010)

Environmental data retrieved from high spatial resolution SPOT satellite images were associated with An. arabiensis densities in Dakar urban setting, which allowed to generate malaria transmission risk maps.

Country: 
City: 

Conference Report | MALVAC 2009: Progress and Challenges in Development of Whole Organism Malaria Vaccines for Endemic Countries, 3–4 June 2009, Dakar, Senegal

July 6, 2010 - 07:42 -- Patrick Sampao
Author(s): 
M. Pinder, V.S. Moorthy, B.D. Akanmori, B. Genton, G.V. Brown
Reference: 
Vaccine, Volume 28, Issue 30, 5 July 2010, Pages 4695-4702

A group of leading scientists, clinical trialists and stakeholders, together with representatives of regulatory authorities including some from African countries, met recently to document the issues that will require detailed consideration to assess this promising approach. Questions related to scale-up, quality, purity and consistency of a manufacturing process using mosquitoes to generate a commercial product, and demonstration of the stability of attenuated sporozoites will need further work.

Country: 
City: 
Medical Condition: 
Medical Treatment: 
Subscribe to RSS - Dakar